The SHH antagonist cyclopamine acts additively with BMP-2, and -4 to suppress GNPs and SHH-group medulloblastoma suggesting that BMP agonists could be used in combination with SHH-antagonists, both potentially at lower levels than alone, to reduce the potential side effects of the individual targeted therapies. This evidence concerns the gene BMP2 and medulloblastoma.